Financial Performance - The company's operating revenue for the third quarter was RMB 499,511,815.43, representing a year-on-year increase of 55.01%[4] - Net profit attributable to shareholders for the third quarter was RMB 260,913,556.78, showing a significant year-on-year growth of 176.77%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 260,340,236.28, with a year-on-year increase of 195.97%[4] - The basic earnings per share for the third quarter was RMB 0.49, an increase of 88.46% compared to the same period last year[5] - The diluted earnings per share for the third quarter was RMB 0.49, with an increase of 88.46% compared to the same period last year[5] - The company reported a net profit attributable to shareholders for the year-to-date of 154.85%, driven by business growth and increased financial income[11] - Diluted earnings per share for the year-to-date increased by 76.12%, due to business growth and increased financial income[12] - Total revenue for the first three quarters of 2022 reached ¥1,276,392,981.45, a significant increase from ¥856,804,399.15 in the same period of 2021, representing a growth of approximately 49%[22] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥632,033,151.04, up from ¥248,006,161.31 in 2021, reflecting a growth of approximately 154%[24] - Basic earnings per share for the first three quarters of 2022 were ¥1.18, compared to ¥0.68 in the same period of 2021, marking an increase of about 74%[25] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was RMB 778,288,380.46, representing a year-on-year increase of 67.93%[4] - Cash flow from operating activities for the year-to-date increased by 67.93%, due to increased sales collections and interest income[11] - Cash inflow from operating activities in the first three quarters of 2022 was ¥2,085,281,684.08, compared to ¥1,422,490,961.55 in 2021, showing an increase of approximately 47%[28] - The total assets at the end of the reporting period amounted to RMB 10,079,078,937.04, reflecting an increase of 18.06% from the end of the previous year[5] - Current assets totaled approximately 5.72 billion RMB, slightly down from 5.81 billion RMB at the end of 2021, indicating a decrease of about 1.2%[18] - The company's cash and cash equivalents were reported at approximately 2.87 billion RMB, down from 4.15 billion RMB at the end of 2021, a decline of about 30.8%[17] - The total cash and cash equivalents at the end of the third quarter of 2022 were approximately 2.85 billion, down from 4.11 billion at the end of the same period in 2021[31] - The company reported a net increase in cash and cash equivalents of approximately -1.30 billion in the first three quarters of 2022, compared to an increase of 3.81 billion in the same period of 2021[31] Liabilities and Equity - The total liabilities increased to approximately 2.41 billion RMB from 1.39 billion RMB, representing a growth of about 73.5%[20] - The company's equity attributable to shareholders rose to approximately 7.66 billion RMB, compared to 7.14 billion RMB at the end of 2021, an increase of about 7.4%[20] Inventory and Investments - The company reported a significant increase in inventory, which rose to approximately 2.21 billion RMB from 700.59 million RMB, a growth of about 215.5%[18] - The long-term investments decreased slightly to approximately 23.66 million RMB from 25.29 million RMB, a decline of about 6.5%[18] - The company experienced a decrease in investment income from joint ventures and associates, reporting a loss of ¥1,632,476.09 in the first three quarters of 2022[23] Operational Highlights - The company has secured a strong order backlog of over 4.6 billion RMB, ensuring robust future revenue growth[16] - The company has implemented effective measures to ensure the smooth delivery of orders, which is expected to positively impact future performance[16] - The company is focusing on new product development and market expansion strategies to enhance its competitive position in the industry[16] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥50,053,890.87, up from ¥35,019,894.79 in 2021, indicating a growth of about 43%[22] Other Financial Metrics - The company reported a loss of RMB 4,880,000 from the valuation changes of trading financial assets during the year-to-date[6] - The company recognized government subsidies amounting to RMB 8,457,000 for the year-to-date, compared to RMB 2,361,000 in the same period last year[7] - The company recorded a net loss of -3,089,926.69 from fair value changes in financial assets and liabilities[10] - The company has not defined any non-recurring gains and losses as recurring gains and losses[10] - Other comprehensive income after tax for the first three quarters of 2022 was ¥35,188,864.58, compared to -¥1,441,837.91 in 2021, indicating a positive turnaround[24]

Financial Performance - JOINN Laboratories reported a revenue of 83 million RMB for the first half of 2022, reflecting a significant growth compared to the previous period[1]. - Revenue for the six months ended June 30, 2022, was RMB 776,881 thousand, representing a 45.3% increase compared to RMB 534,556 thousand in 2021[27]. - Gross profit for the same period was RMB 377,942 thousand, up 40.7% from RMB 268,571 thousand in 2021[27]. - Net profit for the period reached RMB 370,384 thousand, a significant increase of 141.9% from RMB 153,093 thousand in 2021[27]. - Basic earnings per share increased by 125.6% to RMB 0.97 from RMB 0.43 in the previous year[27]. - Total comprehensive income for the period was RMB 388,471 thousand, compared to RMB 150,725 thousand, reflecting a growth of 157.5%[122]. - The company reported a net profit of RMB 371,120 thousand for the six months ended June 30, 2022, compared to RMB 153,735 thousand for the same period in 2021, representing a significant increase[128]. - Cash generated from operating activities for the six months ended June 30, 2022, was RMB 545,494 thousand, compared to RMB 202,465 thousand for the same period in 2021, reflecting improved operational efficiency[131]. Growth and Expansion - The company has expanded its user base, with a 25% increase in clients year-over-year, indicating strong demand for its services[1]. - JOINN Laboratories projects a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - JOINN Laboratories aims to enter the Southeast Asian market by the end of 2023, which is expected to increase its market share significantly[1]. - The company is exploring potential acquisitions to enhance its market position, targeting companies with complementary services[1]. - The company has established strategic partnerships with three major pharmaceutical companies to enhance its service offerings[1]. - The company plans to establish a drug safety evaluation center in Guangzhou and a GLP-compliant non-clinical research laboratory in Chongqing, with operations expected to start in 2023[57]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to expand its presence in the North American pharmaceutical market[57]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 20 million RMB for the development of new technologies and products in the upcoming year[1]. - The company is committed to ensuring stable operations and sustainable development in the future[29]. - The company has optimized various drug evaluation models, including those for ophthalmic and otologic drugs, enhancing its technical capabilities[35]. - The company is actively participating in a national project for the research of a new DNA vaccine platform, which received approval in the first half of 2022[35]. - The company has created over 30 disease animal models for preclinical drug efficacy evaluation, with plans to expand production capacity[38]. Operational Efficiency - The company reported a 30% increase in operational efficiency due to the implementation of new technologies in its laboratories[1]. - The company plans to integrate industry resources and deploy new business capabilities and service models to enhance operational efficiency[29]. - The company has established a wholly-owned subsidiary, Beijing Zhaoyan Drug Testing Research Co., Ltd., to enhance its cell testing business and support innovative drug development[37]. Financial Position - Total assets as of June 30, 2022, were RMB 10,646,728 thousand, reflecting a 24.7% increase from RMB 8,537,077 thousand at the end of 2021[28]. - Total liabilities increased by 132.7% to RMB 3,240,946 thousand from RMB 1,392,641 thousand in 2021[28]. - The company maintained a stable capital structure with a debt-to-equity ratio of 0.1% as of June 30, 2022, unchanged from December 31, 2021[52]. - As of June 30, 2022, cash and cash equivalents were RMB 3,801.0 million, a decrease of 8.5% from RMB 4,154.1 million at the end of 2021[51]. Employee and Shareholder Information - Employee costs totaled approximately RMB 303.0 million, up from RMB 212.7 million in the same period last year[56]. - The company has expanded its professional service team to over 2,600 members, an increase of nearly 500 from the end of 2021[31]. - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2022[62]. - The company has granted a total of 3,785,000 stock options under various incentive plans, with an average exercise price of RMB 59.49 as of June 30, 2022[193]. Market Performance - The total order amount as of June 30, 2022, reached over RMB 4.1 billion, providing a solid foundation for future performance[39]. - The company signed orders exceeding RMB 2 billion in overseas markets, with a year-on-year growth of nearly 30%[41]. - The marketing efforts in the first half of 2022 resulted in over RMB 20 billion in signed orders, with domestic orders exceeding RMB 18 billion, a year-on-year increase of over 50%[40]. Sustainability and Corporate Governance - JOINN Laboratories is committed to sustainability, with plans to reduce its carbon footprint by 25% over the next five years[1]. - The company has adopted corporate governance principles and has complied with applicable code provisions during the six months ending June 30, 2022[110]. - There have been no significant litigation or arbitration cases from the listing date to June 30, 2022[112].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[4]. - The net profit attributable to shareholders for the same period was 300 million RMB, up 20% compared to the previous year[4]. - The company's operating revenue for the first half of 2022 reached RMB 776,881,166.02, representing a 45.33% increase compared to RMB 534,556,471.63 in the same period last year[15]. - The net profit attributable to shareholders for the first half of 2022 was RMB 371,119,594.26, a significant increase of 141.40% from RMB 153,734,926.32 in the previous year[15]. - The net cash flow from operating activities for the first half of 2022 was RMB 545,493,427.60, which is a 169.43% increase from RMB 202,465,705.85 in the previous year[15]. - Future guidance indicates a revenue growth target of 20% for the full year 2022[4]. - The total order amount on hand reached over 4.1 billion RMB, providing a solid foundation for future performance[57]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[4]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[4]. - The company is focusing on expanding its market presence in the CRO and experimental model sectors, driven by increasing domestic and international demand[25]. Research and Development - The company has allocated 200 million RMB for R&D in 2022, a 30% increase from the previous year[4]. - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials by Q4 2022[4]. - The company is developing a leading genetic resource and gene engineering technology platform for creating animal disease models for new drug development[34]. - The company has established a comprehensive drug screening platform for both in vitro and in vivo evaluations, improving the efficiency of drug development[46]. Financial Position - The total assets of the company at the end of the reporting period amounted to RMB 10,646,728,994.36, marking a 24.71% increase from RMB 8,537,077,111.40 at the end of the previous year[15]. - The net assets attributable to shareholders at the end of the reporting period were RMB 7,398,296,481.53, showing a 3.67% increase from RMB 7,136,214,378.04 at the end of the previous year[15]. - The company's cash and cash equivalents at the end of the period amounted to ¥3,800,990,974.43, representing 35.69% of total assets, a decrease of 8.50% compared to the previous year[62]. - The company reported a substantial increase in productive biological assets, which reached ¥777,775,918.46, a 949.42% increase due to acquisitions and fair value adjustments[63]. Risk Management - The management highlighted potential risks related to regulatory changes and market competition[4]. - The company faces risks related to international economic fluctuations, which may negatively impact the pharmaceutical industry and drug innovation investments due to the ongoing COVID-19 pandemic[73]. Environmental Commitment - The company emphasized its commitment to environmental protection and sustainable development, implementing a comprehensive environmental management system[83]. - The company plans to continue investing in environmental improvements to ensure compliance with pollution discharge standards[83]. - The company ensures compliance with environmental standards, including wastewater discharge limits and air pollutant emission standards, through regular third-party inspections and treatment processes[88]. Shareholder Information - The company granted 675,400 restricted A shares to 505 incentive recipients as part of its equity incentive plan approved on January 28, 2022[80]. - The company distributed cash dividends of 0.36 yuan per share and increased capital reserves by 0.4 shares per share, resulting in a total share capital of 534,191,429 shares[103]. - The largest shareholder, Feng Yuxia, held 85,286,037 shares, representing 22.35% of the total shares[105]. Compliance and Governance - The company has committed to not engaging in any competitive business activities with its controlling shareholders and related parties, ensuring no conflicts of interest[91]. - There were no non-operational fund occupations or guarantee violations reported during the reporting period[96]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[141].

2022 年第一季度报告 单位：元币种：人民币 证券代码：603127 证券简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 270,975,486.87 ...

Financial Performance - The company's operating revenue for Q1 2022 was RMB 270,975,486.87, representing a year-on-year increase of 34.82%[3] - Net profit attributable to shareholders for the same period was RMB 125,347,354.57, reflecting a growth of 34.27% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 66.65% year-on-year, amounting to RMB 132,381,980.64[3] - Basic earnings per share for the quarter were RMB 0.33, up 17.86% year-on-year[3] - The company reported a significant increase in cash inflow from investment activities compared to the previous year, indicating a positive trend in investment returns[27] Cash Flow - The net cash flow from operating activities reached RMB 74,906,349.49, a significant increase of 117.23% compared to the previous year[3] - Cash inflow from investment activities totaled approximately $334.48 million, with a net cash inflow from investment activities of about $72.50 million[27] - The cash flow from operating activities generated a net amount of CNY 74,906,349.49 in Q1 2022, compared to CNY 34,482,082.76 in Q1 2021, indicating a growth of 117.5%[26] - The cash flow from investment activities showed a substantial improvement compared to the previous year's negative cash flow of approximately $66.69 million[27] - The company’s cash position remains strong, with a significant balance of cash and cash equivalents at the end of the reporting period[28] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8,957,151,364.84, an increase of 4.92% from the end of the previous year[4] - Total current assets increased to CNY 6,186,990,976.77 as of March 31, 2022, compared to CNY 5,814,484,316.60 at the end of 2021, representing a growth of 6.4%[14] - Non-current assets totaled CNY 2,770,160,388.07 as of March 31, 2022, slightly up from CNY 2,722,592,794.80 at the end of 2021[15] - Total liabilities increased to CNY 1,685,280,811.53 as of March 31, 2022, compared to CNY 1,392,640,954.56 at the end of 2021, indicating a rise of 20.9%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,729[10] - The top shareholder, Feng Yuxia, holds 89,702,855 shares, accounting for 23.51% of total shares[10] Business Growth - New orders signed exceeded 1 billion RMB, representing a year-on-year growth of over 65%[12] - The total amount of orders on hand reached over 3.6 billion RMB at the end of the reporting period[12] - Operating revenue increased by 34.82% due to business growth[9] - Net profit attributable to shareholders increased by 34.27% driven by business expansion[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 66.65% as a result of business growth[9] Research and Development - Research and development expenses increased to CNY 12,289,064.34 in Q1 2022, compared to CNY 9,878,808.23 in Q1 2021, reflecting a growth of 24.3%[19] - Future outlook includes continued investment in R&D to drive innovation and market expansion strategies[19] Other Financial Metrics - The company reported a fair value loss of RMB 14,472,000 related to trading financial assets, impacting net profit[5] - The unrealized gain from biological assets was RMB 34,494,000, contributing positively to net profit[6] - The company received government subsidies amounting to RMB 2,580,000 during the reporting period[5] - The weighted average return on net assets decreased by 1.34 percentage points due to the full weighting of net assets raised from the Hong Kong stock issuance[9] - The company's total profit for Q1 2022 was CNY 139,756,935.47, up from CNY 104,035,964.94 in Q1 2021, reflecting an increase of 34.4%[20]

Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[6]. - The company achieved a net profit of RMB 300 million, which is an increase of 30% compared to the previous year[6]. - Total revenue for 2021 reached RMB 1,516,680,000, a 40.9% increase from RMB 1,075,905,000 in 2020[14]. - Gross profit for 2021 was RMB 735,678,000, resulting in a gross margin of 48.51%[14]. - Net profit attributable to equity shareholders for 2021 was RMB 557,460,000, up from RMB 312,950,000 in 2020, reflecting an increase of 78.5%[14]. - Basic earnings per share for 2021 were RMB 1.51, compared to RMB 0.99 in 2020, representing a 52.5% increase[14]. - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[6]. - In 2021, the company achieved a revenue growth of approximately 41% year-on-year, with net profit attributable to equity shareholders increasing by about 78%[16]. - The company reported a profit distribution plan for the year ending December 31, 2021, proposing a final dividend of RMB 0.36 per share, up from RMB 0.35 in 2020[73]. - The total amount of the proposed final dividend is approximately RMB 137,248,000, compared to RMB 94,850,000 in 2020[73]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Europe and North America, targeting a 20% increase in international revenue by 2023[6]. - The company plans to continue expanding its market presence and investing in new product development[12]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to upgrade facilities and expand services in the North American pharmaceutical market[48]. - The company is focusing on strategic partnerships with leading pharmaceutical companies to enhance its service offerings[6]. - The company plans to invest in expanding its clinical trial services and strengthen its scientific and regulatory teams to support clinical trial operations[48]. Research and Development - The company is investing RMB 200 million in R&D for new drug development technologies, aiming to launch two new products by the end of 2022[6]. - Research and development efforts are focused on innovative drug discovery and enhancing drug metabolism studies[11]. - The company has established a comprehensive platform for non-clinical evaluation, focusing on innovative drug research and evaluation capabilities across various new technologies and targets[19]. - The company successfully created gene-edited cell lines and animal models for rare disease drug development, enhancing its innovative drug research capabilities[22]. Operational Efficiency - JOINN Laboratories is implementing new operational strategies to improve efficiency, aiming for a 10% reduction in operational costs by 2023[6]. - The company upgraded its laboratory information management system (LIMS) and introduced new document management and employee training systems to enhance operational efficiency[19]. - The company expanded its workforce to over 2,100 professionals by December 31, 2021, enhancing the capabilities of its non-clinical research service team[17]. Acquisitions and Partnerships - JOINN Laboratories has completed the acquisition of Biomedical Research Models, Inc., enhancing its capabilities in preclinical research[6]. - The company is exploring potential mergers and acquisitions to strengthen its market position and capabilities[12]. - The company aims to selectively pursue acquisitions of businesses and assets that complement its growth strategy, particularly in non-clinical research and drug discovery services[52]. Financial Position and Assets - Total assets as of December 31, 2021, amounted to RMB 8,537,077,000, significantly higher than RMB 2,172,902,000 in 2017[15]. - Total liabilities for 2021 were RMB 1,392,641,000, compared to RMB 951,093,000 in 2020[15]. - Net assets for 2021 stood at RMB 7,144,436,000, an increase from RMB 1,221,809,000 in 2017[15]. - Cash and cash equivalents as of December 31, 2021, were RMB 41,541 million, an increase of 1,245.7% from RMB 3,087 million as of December 31, 2020[43]. Risks and Challenges - The company faces regulatory compliance risks due to the need to adhere to multiple laws and regulations across different countries, which could adversely affect its reputation and financial performance[53]. - Talent recruitment risks are heightened as the company expands, necessitating the cultivation and introduction of skilled personnel to meet current and future business needs[54]. - Market competition risks are increasing as competitors expand capacity and facilities, necessitating the company to maintain its core competitive advantages[55]. - The ongoing COVID-19 pandemic poses challenges to daily operations, and future developments in the pandemic could impact business operations depending on national policies[59]. Corporate Governance - The board consists of 10 members, with executive directors having service contracts established in February 2021 for an initial term of three years[83]. - The company has established a framework for maintaining shareholder interests and enhancing corporate value through effective governance practices[152]. - The board of directors held seven meetings during the reporting period, exceeding the minimum requirement of four meetings per year[175]. - The company has adopted a board nomination policy outlining criteria for selecting candidates for appointment or reappointment[166]. Shareholder Relations - The company emphasizes the importance of effective communication with shareholders to enhance investor relations[195]. - Shareholders holding more than 3% of the company's shares can propose temporary motions at least 10 days before the annual general meeting[193]. - The company has established a policy to maintain communication with shareholders, ensuring timely responses to shareholder concerns and suggestions[195]. Employee and Labor Relations - The company has established a union in China to represent employees and ensure compliance with labor laws and regulations[138]. - The employer matches employee contributions to the 401(k) plan up to 4% of eligible wages, providing a safety net for retirement savings[141]. Environmental and Social Responsibility - The company has established detailed internal rules for environmental protection, with no additional costs incurred for compliance as of December 31, 2021[74]. - The company emphasizes compliance with anti-bribery and anti-corruption regulations to mitigate risks associated with bribery and corruption[138]. - The company made donations amounting to RMB 1.2 million during the reporting period[151].

Financial Performance - The company's operating revenue for 2021 was approximately ¥1.52 billion, representing a 40.97% increase compared to ¥1.08 billion in 2020[17]. - The net profit attributable to shareholders for 2021 was approximately ¥557.46 million, a 76.96% increase from ¥315.01 million in 2020[17]. - The cash flow generated from operating activities in 2021 was approximately ¥685.66 million, up 60.06% from ¥428.39 million in 2020[17]. - The total assets at the end of 2021 were approximately ¥8.54 billion, a 305.02% increase from ¥2.11 billion at the end of 2020[17]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥7.14 billion, reflecting a 482.60% increase from ¥1.22 billion at the end of 2020[17]. - The basic earnings per share for 2021 were ¥1.51, a 51.00% increase compared to ¥1.00 in 2020[18]. - The diluted earnings per share for 2021 were ¥1.50, representing a 51.52% increase from ¥0.99 in 2020[18]. - The weighted average return on equity for 2021 was 9.42%, down 21.36% from 30.78% in 2020[18]. - The company achieved a revenue of CNY 1,516.68 million in 2021, representing a year-on-year growth of 40.97%[64]. - The net profit attributable to shareholders was CNY 557.82 million, reflecting a year-on-year increase of 77.08%[64]. Investments and Capital Structure - The company plans to distribute a cash dividend of 3.6 CNY per 10 shares (including tax) and to increase capital by converting 4 shares for every 10 shares held[3]. - The company made strategic investments in Changchun Baike Biotechnology Co., Ltd. and Beijing Zhaoyan Biotechnology Co., Ltd., with total investments of ¥4,362 million and ¥5,000 million respectively, enhancing business cooperation and market competitiveness[78]. - The fair value of financial products increased to ¥605,533,634.18, up from ¥238,902,999.99 in the previous period, reflecting a strong growth in investment performance[80]. - The company reported a total of 1,135,000,000 RMB in entrusted financial management, with an outstanding balance of 600,000,000 RMB[160]. - The total number of shares increased from 227,454,729 to 381,246,492 shares due to various stock options and capital increases[162][164][166]. Operational Developments - The company expanded its workforce to over 2,100 professionals by the end of 2021, enhancing its service capabilities[24]. - A new 7,500 square meter breeding facility was completed and put into use by the end of 2021, supporting increased operational capacity[25]. - The company is constructing an additional 20,000 square meters of facilities to meet growing experimental demands, expected to be operational in the second half of 2022[25]. - Approximately 6,000 square meters of new experimental facilities were renovated in California to alleviate capacity constraints at the overseas subsidiary BIOMERE[26]. - The company has established a competitive compensation scheme, including stock incentives, to enhance employee motivation and retention[24]. Market Position and Strategy - The company achieved a total order amount of approximately RMB 29 billion in 2021, providing a solid foundation for future performance[33]. - The company signed orders exceeding RMB 28 billion in 2021, with domestic orders amounting to over RMB 25.5 billion, representing a year-on-year growth of approximately 65%[34]. - The overseas subsidiary BIOMERE secured orders of about RMB 2.8 billion in 2021, reflecting a year-on-year increase of approximately 75%[36]. - The company is focused on expanding its market presence through strategic partnerships and investments in biotechnology, aiming for long-term growth[109]. - The company plans to expand its market presence and is focusing on new product development and technological advancements[107]. Governance and Compliance - The financial report has been audited by KPMG Huazhen, which issued a standard unqualified opinion[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company maintained independent operations and governance, ensuring no interference from controlling shareholders during the reporting period[100]. - The company has implemented measures to maintain independence in assets, personnel, and operations from controlling shareholders[101]. - The company has not faced any penalties from securities regulatory authorities in the past three years[114]. Research and Development - The company is committed to adhering to Good Laboratory Practice (GLP) standards in its research activities[7]. - The company has established a complete cell testing system in 2021, addressing the quality inspection needs for cell lines and cell banks, which is expected to become a new growth point[31]. - The company’s clinical sample testing segment has expanded to include a wide range of innovative drugs, significantly reducing method transfer time for clients[29]. - The company has developed specialized evaluation techniques for various innovative biopharmaceuticals, including gene drugs and complex antibody drugs, creating new competitive advantages[55]. - The company is investing in research and development to innovate new products, aiming to launch at least three new products in the next fiscal year[107]. Environmental Responsibility - The company emphasized the importance of environmental protection and sustainable development in its operational policies[140]. - The company has established a comprehensive environmental management system and conducts regular checks on its environmental performance[140]. - The company has committed to improving its wastewater treatment facilities to meet higher standards[143]. - The company implemented measures to reduce carbon emissions, including the use of energy-efficient LED lights and electric vehicles[144]. - The company conducted regular third-party inspections to ensure compliance with environmental discharge standards[143]. Risks and Challenges - The company faces risks from fluctuating international economic conditions and potential reductions in pharmaceutical innovation investments due to the ongoing COVID-19 pandemic[96]. - The company acknowledges the challenges posed by the COVID-19 pandemic and its potential impact on business operations, despite current control measures[98]. - The company is committed to maintaining its core competitive advantages amid increasing market competition in the non-clinical CRO industry[97]. - The company is focused on developing new technical methods to adapt to industry trends and maintain its leading position in the market[98].

Financial Performance - Q3 2021 revenue reached ¥322,247,927.52, an increase of 37.62% year-over-year[2] - Net profit attributable to shareholders was ¥94,271,234.99, up 76.76% compared to the same period last year[2] - Net profit excluding non-recurring gains and losses for the period was ¥87,962,581.12, reflecting a 94.72% increase year-over-year[2] - Basic earnings per share for Q3 2021 was ¥0.36, up 111.76% from the previous year[3] - Total operating revenue for the first three quarters of 2021 reached ¥856,804,399.15, a 35.7% increase from ¥631,513,285.48 in the same period of 2020[15] - Net profit for the third quarter of 2021 was ¥247,009,521.78, compared to ¥142,479,212.65 in the same quarter of 2020, representing a 73.2% increase[17] - The net profit attributable to shareholders of the parent company for the third quarter of 2021 was ¥248,006,161.31, up from ¥143,556,153.79 in the previous year[19] - Basic earnings per share for the third quarter of 2021 were ¥0.95, compared to ¥0.45 in the same quarter of 2020[19] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period was ¥463,447,574.19, showing a 106.82% increase[3] - The company reported a significant increase in cash flow due to higher sales collections resulting from business growth[7] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 463,447,574.19, a significant increase of 106.7% compared to CNY 224,084,428.91 in the same period of 2020[20] - Total cash inflow from investment activities was CNY 404,057,385.13, up from CNY 331,436,170.51 in the previous year, while cash outflow for investment activities surged to CNY 2,290,934,619.51 from CNY 508,987,148.73[21] - The cash flow from investment activities showed a net outflow of CNY 1,886,877,234.38, compared to a net outflow of CNY 177,550,978.22 in the previous year, indicating increased investment activities[21] - The company’s cash inflow from financing activities was primarily driven by CNY 5,407,415,864.64 received from investments, a significant increase from CNY 32,872,124.88 in the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,201,780,654.41, a 289.11% increase from the previous year[3] - The total assets of the company as of September 30, 2021, amount to 8,201,780,654.41 RMB, compared to 2,107,821,636.06 RMB at the end of 2020[13] - The total liabilities of the company as of September 30, 2021, are 1,237,063,156.75 RMB, compared to 760,042,162.51 RMB at the end of 2020[13] - Total liabilities as of the end of the third quarter of 2021 amounted to ¥1,388,193,843.40, significantly higher than ¥883,657,479.78 at the end of the third quarter of 2020[17] - Total current assets as of the end of the reporting period were CNY 1,182,910,934.76, slightly down from CNY 1,182,686,692.14 at the beginning of the year[23] - Total liabilities decreased to $883,657,479.78 from $951,093,100.06, representing a reduction of about 7%[24] - Non-current liabilities decreased significantly from $176,785,397.88 to $123,615,317.27, a drop of around 30%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,231[8] - The largest shareholder, Feng Yuxia, holds 89,702,855 shares, representing 23.57% of the total shares[9] - Total equity attributable to shareholders of the parent company reached ¥6,815,318,386.55, compared to ¥1,224,899,092.29 in the previous year[17] Business Growth and Orders - The increase in revenue and net profit was primarily driven by business growth and interest income from raised funds[6] - The company has secured over 3 billion RMB in orders as of the end of the reporting period, reflecting a year-on-year increase of over 70% in new orders[10] Research and Development - Research and development expenses for the third quarter of 2021 were ¥35,019,894.79, a decrease from ¥48,885,489.44 in the same period of 2020[17] Accounting and Financial Reporting - The company has implemented revised accounting standards for leases effective January 1, 2021, impacting financial reporting[26]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2021, representing a year-on-year increase of 25%[1]. - The net profit attributable to shareholders was 300 million RMB, up 30% compared to the same period last year[1]. - The company's operating revenue for the first half of the year reached ¥534,556,471.63, representing a 34.53% increase compared to ¥397,354,998.31 in the same period last year[14]. - The net profit attributable to shareholders was ¥153,734,926.32, a significant increase of 70.39% from ¥90,223,461.98 in the previous year[14]. - The net cash flow from operating activities was ¥202,465,705.85, up 31.18% from ¥154,344,394.21 year-on-year[14]. - The total assets of the company increased to ¥7,869,165,124.10, reflecting a 273.33% growth compared to ¥2,107,821,636.06 at the end of the previous year[14]. - The net assets attributable to shareholders surged to ¥6,610,662,672.42, marking a 439.69% increase from ¥1,224,899,092.29 at the end of last year[14]. - Basic earnings per share rose to ¥0.60, a 50.00% increase from ¥0.40 in the same period last year[15]. - The diluted earnings per share increased to ¥0.59, up 47.50% from ¥0.40 year-on-year[15]. - The company reported a weighted average return on equity of 3.17%, down 6.96 percentage points from 10.13% in the previous year[15]. Market Expansion and Client Growth - The company expanded its client base by 20%, reaching a total of 200 clients in the first half of 2021[1]. - The company aims to enter two new international markets by the end of 2022, focusing on Europe and North America[1]. - The company’s orders in the first half of 2021 reached approximately RMB 400 million, a year-on-year increase of over 150%[51]. - The overseas subsidiary BIOMERE secured orders of approximately USD 21.5 million, reflecting a year-on-year growth of over 60%[57]. - The company’s domestic orders from overseas clients reached approximately RMB 73 million, a year-on-year increase of over 80%[57]. Research and Development - The number of new drug development projects increased by 15%, with a total of 50 active projects as of June 30, 2021[1]. - The company plans to invest 200 million RMB in R&D for new technologies and products in the next fiscal year[1]. - The company is enhancing its service capabilities and applying new technologies, particularly in the evaluation of innovative drugs, which supports future business expansion[27]. - The company is focusing on developing a leading, efficient, and stable genetic resource and gene engineering technology platform for experimental animals, particularly for new drug development[25]. - The company has established a unique golden industrial chain for preclinical research services, clinical trials, and related services, ensuring high-quality service for clients[18]. Operational Efficiency and Compliance - The company ensures compliance with regulatory requirements and quality management standards in all its services, thereby reducing the risk and increasing the efficiency of drug development for clients[22]. - The company has established a strict procurement process, ensuring effective control over procurement applications, approvals, inquiries, supplier selection, and payments[25]. - The company has implemented a laboratory information management system (LIMS) to improve work efficiency and ensure compliance with GLP regulations, significantly increasing data reliability and integrity[40]. - The company has optimized its organizational structure and compensation system to enhance employee engagement and improve service efficiency[48]. Financial Position and Assets - The company's total assets increased to CNY 115,943.39 million as of June 30, 2021, compared to CNY 79,488.33 million in the same period of 2020, representing a growth of 46.0%[69]. - The total liabilities increased to approximately ¥1.10 billion from ¥760.04 million, reflecting a growth of about 45%[107]. - The company's long-term equity investments increased to approximately ¥102.44 million from ¥64.44 million, showing a growth of about 59%[107]. - The total current assets as of June 30, 2021, amounted to approximately ¥5.37 billion, a significant increase from ¥1.18 billion as of December 31, 2020, reflecting a growth of about 354%[106]. - Cash and cash equivalents increased to approximately ¥4.20 billion from ¥308.69 million, representing a growth of over 1,260%[106]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which may impact future performance[1]. - Intense market competition in the preclinical CRO industry poses risks, with competitors expanding capacity and facilities, potentially impacting profitability if the company fails to maintain its competitive edge[72]. - The company faces talent recruitment risks due to the urgent need for management, technical, and marketing personnel as business scales and expands[71]. - The COVID-19 pandemic has posed operational challenges, although its overall impact on production has been limited; future developments remain uncertain[76]. Environmental and Social Responsibility - Environmental management practices are in place, with a focus on pollution prevention and sustainable development, including regular third-party inspections of emissions[84]. - The company has implemented measures to reduce carbon emissions, including the use of energy-efficient LED lighting and electric vehicles[89]. - The company has established a wastewater treatment facility that meets the standards for discharge into public systems[88]. - The company has engaged third-party testing to ensure compliance with environmental discharge standards[88]. Shareholder and Corporate Governance - The company reported a total share count of 270,820,329 after the issuance of 43,365,600 new shares, representing a 19.1% increase in total shares[96]. - The company has committed to avoiding any competition with its controlling shareholders and related parties, ensuring compliance with competitive regulations[90]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period[80]. - The company has not reported any violations or penalties related to its directors, supervisors, or controlling shareholders[94].